Genetic Technologies shares the company’s latest milestones along with our clinical adoption of the Company’s groundbreaking geneType Risk Assessment Tests routinely across 12 states in the United States and nationally in Australia. The geneType team has achieved clinical proof of concept in key markets including general practice, oncology, and gynecology with repeat sales in each of these markets. Clinical adoption of geneType is now in more than 12 US States, Canada and nationally in Australia. Commercial tests received for the 6 months ending March 31, 2024 increased 543%, when compared with the same period last year, demonstrating the company is well on a pathway to profitability.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GENE:
- Genetic Technologies Innovates Breast Cancer Screening
- Genetic Technologies to pilot GeneType in Breast Screen centers across U.S.
- Genetic Technologies Advances Women’s Health Literacy
- Genetic Technologies, Humanise Health launch ‘Know Your Risk’ event
- Genetic Technologies reports impact of new digital strategy